Unknown

Dataset Information

Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.


ABSTRACT: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. Previous clinical trials with oral multikinase inhibitors were negative, which has been attributed in part to inadvertent drug interaction with mitotane. Cabozantinib (CABO) is an inhibitor of c-MET, vascular endothelial growth factor receptor 2, AXL, and RET and approved for advanced kidney cancer, liver carcinoma after previous sorafenib, and medullary thyroid carcinoma. To investigate the clinical efficacy and safety of CABO monotherapy in ACC patients. Retrospective cohort study. Three referral centers for ACC (Germany, United States). Sixteen patients (13 female) with progressive ACC received CABO after previous mitotane in

SUBMITTER: Kroiss M 

PROVIDER: S-EPMC8204945 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature